Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO **Application Number** Not yet assigned (Continuation of 09/857,332) INFORMATION DISCLOSURE Filing Date March 23, 2004 STATEMENT BY APPLICANT **First Named Inventor** N. Phillips (use as many sheets as necessary **Group Art Unit** Not yet assigned **Examiner Name** Not yet assigned Sheet of 2 **Attorney Docket Number** 02811-0152 (42368-298888)

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
ST=N	1	6,326,357		Phillips et al.	12-04-2001		
gur	2	6,329,347		Phillips et al.	12-11-2001		
	ļ					<del></del>	
	-	<del> </del>					
		<u> </u>				•	
	-						
						****	
	i						
	ļ						
	-						
				· · · · · · · · · · · · · · · · · · ·			
		1					

				FOR	EIGN PATENT DOCUME	NTS		
Examiner Initials	Cite No.	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	$\top$
		Office3	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	14
ark	3	wo	99 07383		Bioniche Inc.	02-18-1999		
8								
							····	
						<u> </u>	****	
	l							

11-12-05 Examiner Date Signature Considered

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO **Application Number** Not yet assigned (Continuation of 09/857,332) **INFORMATION DISCLOSURE** Filing Date March 23, 2004

STATEMENT BY APPLICANT First Named Inventor N. Phillips (use as many sheets as necessary **Group Art Unit** Not yet assigned **Examiner Name** Not yet assigned Attorney Docket Number 02811-0152 (42368-298888) Sheet 2 of 2

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
	4	publisher, city and/or country where published Filion, M.C., et al, Mycobacterial Dna Induces Apoptosis In Myeloid Leukemia Cell	
$\alpha$		Lines", Thirty-Ninth Annual Meeting Of The American Society Of Hematology, San	
$\nearrow$		Diego, California, Vol. 90 (10 Supp., 1 part 2) (December 5-9, 1997)	1
$\sim$	5	Filion, M.C., et al., "Mycobacterial Cell Wall-DNA Complex Induces Apoptosis in	
		Cancer Cells", Database Biosis Online, Biosciences Information Service, Philadelphia,	
\		PA, XP002133100, J. of Pharmacy and Pharmacology, 135 <sup>th</sup> Meeting of the British	
		Pharmaceutical Conference Eastbourne, England UK, Vol. 50, p. 39 (September 8-11,	
1		1998)	
	6	Filion, M.C., et al., "Mycobacterial Phlei Cell Wall Complex, a New Anti-Tumoral	
		Agent, Induces IL-12 Synthesis By Monocyte-Macrophages Via Associated DNA",	
		Third-Ninth Annual Meeting of the American Society of Hematology, San Diego,	
		California, Blood, Vol. 90 (10 Supp. 1 part 2) (December 5-9 1997)	
1	7	Filion, et al., "Toxicity and Immunomodulatory Activity of Liposomal Vectors	
		Formulated with Cationic Lipids Toward Immune Effector Cells", Biochim. Biophys.	
		Acta, Vol. 1329, pp. 345-356 (1997)	
	8	Phillips, et al, "Influence of Phosphlipid Compositions on Antibody Responses to	
		Liposome Encapsulated Protein and Peptide Antigens", Vaccine, Vol. 14, No. 9, pp. 898-	
		904 (1996)	
$\bigcirc$	9	Yamamoto, S., et al., "In vitro Augmentation of Natural Killer Cell Activity and	
$(X \mid X)$		Production of Interferon- $\alpha/\beta$ and $-y$ with Deoxyribonucleic Acid Fraction From	
<del>                                   </del>		Mycobacterium bovis BCG", Jpn. J. Cancer Res., Vol. 79, pp 866-873	
0			
:			
.			1